Moshe Talpaz
Division of Hematology/Oncology
University of Michigan Medical Center, USA
Moshe Talpaz, M.D., is a leading clinical investigator in hematologic malignancies and a pioneer in the quest to understand, treat and ultimately cure chronic myeloid leukemia (CML), a cancer of the white blood cells. He is internationally known for his role in the development of targeted cancer therapeutics.
Dr. Talpaz completed his medical training at the Hebrew University and Hadassah Medical School in Jerusalem, Israel, and his residency in internal medicine at the Kaplan Hospital in Rehovot, Israel. After a postdoctoral fellowship at the University of Texas M.D. Anderson Cancer Center in Houston, Dr. Talpaz joined the faculty there in 1981 and rose from an assistant professor of medicine to a tenured professor. He was chair of Bioimmunotherapy Department at Anderson when he was recruited to join the University of Michigan faculty in 2006, bringing with him his extraordinary expertise in immunotherapy, cytokines and biologic response modifiers.
Dr. Talpaz has published more than 450 scientific articles and numerous reviews and book chapters on CML. More than anything, he sees himself as fortunate for being able to be part of this remarkable evolution in therapy, which he believes will have a major impact on the treatment of cancer as a whole.
The exploration of new generations of tyrosine kinase inhibitors and their ability to overcome resistance to Gleevec and their potential activity against many other malignancies.
